200 mg concentrate for solution for infusion
Sponsors
CHUR Of Besançon, Centre Hospitalier Regional Universitaire, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, Fondation Franc.Cancerologie Digestive, Fondation Franc.Cancerologie Digestive, Institut Curie, Institut Curie, Centre Hospitalier Universitaire De Grenoble
Conditions
Early and metastatic triple negative breast cancerHepatocellular Carcinoma (Morpheus-Neo HCC)Hepatocellular carcinomaMetastatic CancerMicrosatellite stable colorectal cancer patientsNon−Small Cell Lung CancerPatients with locally advancedPersistent or Recurrent Rare Epithelial Ovarian Tumors
Phase 1
A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)
CompletedCTIS2022-502840-11-00
Start: 2023-11-28End: 2025-10-23Target: 55Updated: 2025-12-08
PHASE Ib STUDY WITH THE COMBINATION OF LB–100 (PP2A INHIBITOR) AND ATEZOLIZUMAB (PD–L1 INHIBI-TOR) IN METASTATIC COLORECTAL CANCER PATIENTS – The CoLBAt Trial
RecruitingCTIS2023-505534-98-00
Start: 2024-08-01Target: 37Updated: 2025-11-17
Phase 2
TERTIO : Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase
and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a proof of concept randomized phase II study
RecruitingCTIS2022-500643-20-00
Start: 2022-09-27Target: 104Updated: 2025-11-13
PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase II-III study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy
Active, not recruitingCTIS2022-501217-31-00
Start: 2023-03-09Target: 574Updated: 2024-11-27
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
CompletedCTIS2022-502078-17-00
Start: 2022-12-15End: 2024-03-08Target: 196Updated: 2023-08-22
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
Active, not recruitingCTIS2022-501076-26-00
Start: 2018-08-28Target: 109Updated: 2025-08-27
IFCT-2201 ADAPTABLE A non-comparative randomized phase II trial evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced non-squamous NSCLC progressing after immunotherapy and chemotherapy
Active, not recruitingCTIS2022-502103-30-00
Start: 2023-04-25Target: 156Updated: 2024-04-08
"SKYLINE": Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer: A phase II trial
RecruitingCTIS2022-501561-51-00
Start: 2024-03-27Target: 160Updated: 2025-05-07
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors
Active, not recruitingCTIS2023-508194-89-00
Start: 2021-08-30Target: 57Updated: 2026-01-06
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd–Sponsored Trastuzumab Emtansine Study
RecruitingCTIS2023-503479-79-00
Start: 2011-06-17Target: 60Updated: 2025-12-10
MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER”
RecruitingCTIS2023-508201-25-00
Start: 2025-03-12Target: 34Updated: 2025-12-22